Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1142908

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatology: General Practitioners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of GPs with a special interest in dermatology.
tabling member constituency	Wolverhampton South West
tabling member printed	Eleanor Smith
uin	284455
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 17:41:31 answering member 4380 label Biography information for Jo Churchill
tabling member	4609 label Biography information for Eleanor Smith

1143735

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the UK leaving the EU without a deal on the regulatory processes for new medicines for rare conditions.
tabling member constituency	Wolverhampton North East
tabling member printed	Emma Reynolds
uin	285265
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Medicines and Healthcare products regulatory Agency (MHRA), as with all of Government has been working hard to ensure that the United Kingdom is fully prepared for European Union exit under any circumstance. The potential effect that the UK leaving the EU without a deal will have on the regulatory processes for new medicines for rare conditions is being mitigated with clear guidance and close engagement with industry to ensure plans are relevant and fit for purpose.</p><p>Following a public consultation last year, the MHRA has legislated to ensure a smooth transition to national provisions for human medicines, including those for rare diseases. Indeed, for medicines for rare diseases the UK will offer incentives, some fees will be waived, with others fully or partially refunded, to encourage the development and marketing of such medicines.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 09/09/2019 17:42:36 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	4077 label Biography information for Emma Reynolds

1143736

registered interest
date	02/09/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the capacity requirements for the Medicines and healthcare products regulatory agency after the UK leaves the EU.
tabling member constituency	Wolverhampton North East
tabling member printed	Emma Reynolds
uin	285266
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Medicines and Healthcare products Regulatory Agency has assessed the capacity that will be required in both a deal and a ‘no deal’ European Union exit scenario. This is based on scrutiny of resource and careful assessment of the Agency’s ability to support the pharmaceutical and medical device industries.</p><p>Any gaps in resource have been identified by the agency, and sufficiently addressed. In the case of a ‘no deal’ scenario, the Agency has developed and is prepared to implement a new IT system that will sufficiently support industry to continue to operate in a smooth transition. The Agency continues to engage industry to ensure any concerns are addressed and that appropriate transparency is maintained.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 09/09/2019 17:40:45 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	4077 label Biography information for Emma Reynolds